In this issue:
Lopinavir-ritonavir for severe COVID-19
Remdesivir for COVID-19
Remdesivir for 5 or 10 days for severe COVID-19
Tetravalent dengue vaccine in children: phase II study
Tetravalent dengue vaccine in children: phase III study
Oseltamivir in low-risk adults with influenza
Aminoglycoside-based regimen for pyelonephritis
Doxycycline for infrarenal abdominal aortic aneurysms
Long-term tuberculosis reactivation rates in Australian migrants
Mortality in Escherichia coli bloodstream infections
Please login below to download this issue (PDF)